期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

hTERT启动子调控的PUMA腺病毒转染卵巢癌COC1细胞的研究 被引量：1

Recombinant adenovirus containing PUMA gene regulated by human telomerase reverse transcriptase promoter transfected into ovarian cancer COC1 cells
下载PDF
导出
摘要 目的探讨卵巢癌COC1细胞中大量表达p53正向凋亡调控因子(PUMA)在抑制COC1细胞中的作用。方法采用人端粒酶逆转录酶(hTERT)启动子调控的PUMA基因腺病毒载体(Ad-hTERT-PUMA)转染卵巢癌COC1细胞,通过细胞活性检测试剂盒和凋亡试剂盒研究COC1细胞的生长情况,同时分析表达PUMA的水平。结果转染Ad-hTERT-PUMA后,PUMA大量表达,抑制COC1细胞生长,促进细胞凋亡。结论 Ad-hTERT-PUMA成功转染卵巢癌COC1细胞并大量表达,起到了抑制卵巢癌细胞增长的作用。 Objective To over-express the P53 upregulated modulator of apoptosis（PUMA） in ovarian cancer COC1 cells for playing the role to restrain the cell growth .Methods Adenovirus vector （Ad）-human telomerase reverse transcriptase promoter （hTERT）-PUMA was transfected into ovarian cancer COC1 cells .Then the growth of COC1 cells was studied by CCK-8 and the apoptosis kit and the level of PUMA was analyzed .Results After transfection of Ad-hTERT-PUMA ,PUMA was over-expressed in COC1 cells ,which restrained the cells growth and promoted the cell apoptosis .Conclusion Ad-hTERT-PUMA is successfully transfected into ovarian cancer COC1 cells and PUMA is over-expressed to play the role for restraining the cells growth .
作者 李雨聪 王冬
机构地区 重庆市肿瘤研究所妇瘤科
出处 《重庆医学》 CAS CSCD 北大核心 2014年第26期3452-3454,共3页 Chongqing medicine
基金 重庆市卫生局课题(2011-2-366)
关键词 端粒 末端转移酶 p53正向凋亡调控因子 卵巢肿瘤 腺病毒科 telomerase P53 up-regulate modulator of apoptosis ovarian neoplasms adenoviridae
分类号 R737.31 [医药卫生—肿瘤]
  • 相关文献

参考文献12

  • 1Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological Cancer: The size of the problem[J]. Best Pract Res Clin Obstet Gynaecol,2006,20(2) :207-225.
  • 2易晓芳,丰有吉.复发性卵巢癌的化疗进展[J].肿瘤学杂志,2006,12(2):99-102. 被引量：9
  • 3Pastor DM,Irby RB,Poritz LS. Tumor necrosis factor al- pha induces p53 up-regulated modulator of apoptosis ex pression in colorectal cancer cell lines[J]. Dis Colon Rec- tum, 2010,53 (3) : 257-263.
  • 4Michalak EM, Villunger A, Adams JM, et al. In several cell types tumour suppressor p53 induces apoptosis large- ly via Puma but Noxa can contribute[J]. Cell Death Dif- fer,2008,15(6) : 1019-1029.
  • 5Gurzov EN,Germano CM, Cunha DA, et al. p53 up-regu- lated modulator of apoptosis(PUMA) activation contrib- utes to pancreatic beta-cell apoptosis induced by proin- flammatory cytokines and endoplasmic reticulum stress [J]. J Biol Chem,2010,285(26) :19910-19920.
  • 6Zhou Z, Sturgis EM, Liu Z, et al. Genetic variants of a BH3-only pro-apoptotic gene, PUMA, and risk of HPV16-associated squamous cell carcinoma of the head and neck[J]. Mol Carcinog, 2012,51 Suppl 1 :S54-64.
  • 7Spender LC, Carter MJ, O' brien DI, et al. Transforming growth factor-1? directly induces p53-up-regulated modula- tor of apoptosis(PUMA) during the rapid induction of apoptosis in myc-driven B-cell lymphomas[J]. J Biol Chem,2013,288(7) :5198-5209.
  • 8Ma B, Shi J ,Jia L,et al. Over-expression of PUMA corre- lates with the apoptosis of spinal cord cells in rat neuro- pathic intermittent claudication model [J]. PLoS One, 2013,8(5) : e56580.
  • 9Din S, Mason M, Volkers M, et al. Pim-1 preserves mito- chondrial morphology by inhibiting dynamin-related pro- tein 1 transloeation[J]. Proc Natl Acad Sci U S A, 2013, 110(15) :5969-5974.
  • 10Majumdar AS, Hughes DE,Liehtsteiner SP,et al. The te- lomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxiei- ty encountered with constitutive promoters [J]. Gene Ther,2001,8(7) :568-578.

二级参考文献27

  • 1Tewari D,Monk BJ,Hunter M,et al.Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma[J].Invest New Drugs,2004,4:475-480.
  • 2Ferrandina G,Paris I,Ludovisi M,et al.Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer:updated results and long-term survival[J].Gynecol Oncol,2005,98(2):267-273.
  • 3Spriggs D.Optimal sequencing in the treatment of recurrent ovarian cancer[J].Gynecol Oncol,2003,90(Suppl):39-44.
  • 4du Bois A,Quinn M,Thigpen T,et al.2004 consensus statements on the management of ovarian cancer:final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC2004)[J].Ann Oncol,2005,16 (Suppl 8):viii7-viii12.
  • 5Rustin FJS,Bast RC,Kelloff GJ,et al.Use of CA125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer[J].Clin Cancer Res,2004,10:3919-3926.
  • 6Harries M,Gore M.Part Ⅱ:chemotherapy for epithelial ovarian cancer-treatment of recurrent disease[J].Lancet Oncol,2002,3:537-545.
  • 7Penson RT,Dignan F,Seiden MV.et al.Attitudes to chemotherapy in patients with ovarian cancer[J].Gynecol Oncol,2004,94:427-435.
  • 8Eisenhauer EA,Vermorken JB,van Glabbeke M.Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer:a multivariate analysis of 704patients[J].Ann Oncol,1997,8:963-968.
  • 9Jemal A,Murray T,Ward E,et al.Cancer statistics,2005[J].CA Cancer J Clin,2005,55:10-30.
  • 10Daly MB,Ozols RF.Symptoms of ovarian cancer-Where to set the bar?[J].JAMA,2004,291:2755-2756.

共引文献8

同被引文献11

引证文献1

二级引证文献4

重庆医学
2014年 第26期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部